Cryo-Cell International, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Description of Business and Summary of Significant Accounting Policies - Additional Information (Detail)

Description of Business and Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	0 Months Ended		1 Months Ended	12 Months Ended			12 Months Ended				12 Months Ended				0 Months Ended		12 Months Ended
	May 30, 2012 Directors	Feb. 02, 2012	Dec. 31, 2005	Nov. 30, 2013 Agreement Deliverables Segment CompensationPlan	Nov. 30, 2012	Aug. 25, 2011	Nov. 30, 2013 Chief Executive Officer [Member]	Nov. 30, 2013 Saneron [Member]	Nov. 30, 2012 Saneron [Member]	Oct. 10, 2001 Saneron [Member] CCEL Bio-Therapies, Inc. [Member]	Nov. 30, 2013 Employee Stock Incentive Plan [Member]	Nov. 30, 2013 Minimum [Member]	Nov. 30, 2013 Maximum [Member]	Nov. 30, 2013 Mexico [Member]	Oct. 10, 2001 Saneron Therapeutics, Inc. [Member] CCEL Bio-Therapies, Inc. [Member]	Oct. 10, 2001 Saneron Therapeutics, Inc. [Member] Stem Cell Preservation Technologies, Inc. [Member]	Nov. 30, 2013 Credit Concentration Risk [Member]	Nov. 30, 2012 Credit Concentration Risk [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Number of reportable segment				1
Issue of shares by parent and another subsidiary of parent to the share holder of company merged with wholly owned subsidiary															260,000	195,000
Fair value of shares issued by parent and another subsidiary of parent to the share holder of company merged with wholly owned subsidiary															$ 1,924,000	$ 3,900
Non-Controlling interest after merger										43.42%
Ownership interest								34.00%	34.00%
Concentration risk related to supplier				Company dependency on one supplier for the source of collection kits
Percentage of accounts receivable and advances due from certain foreign license affiliates																	42.00%	55.00%
Number of deliverables for revenue recognized				2
Contracted storage periods												1 year	21 years
Deferred revenue recognition period				12 months
Number of licensing agreement made by entity				12
Number of license agreement				2
Cash required to be deposited in bank for issuance of letter of credit				200,000
Certificate of deposit with a principal balance				200,000
Transfer of funds to a Grantor Trust for payments under certain executive employment agreements						2,500,000
Period of doubtful for accounts receivable due from client				30 days
Impairment on long lived assets				0	0
Writing off abandoned patent and trademarks				378,837	52,536
Amortization expense				394,000	74,000
Accumulated amortization				7,123	87,249
Amortization period				20 years
Condition for recording equity losses								0
Minimum percentage probability of realized tax benefit on settlement				50.00%
Provisions for interest or penalties related to uncertain tax positions				0	0
Uncertain tax provisions				0	0
Advertising cost included in selling, general and administrative expenses				615,000	692,000
Trading securities				37,910	13,660
Unrealized holding gain				12,800
Unrealized holding loss					7,100
Payment warranty			50,000
Increased payment warranty		75,000
Additional payment warranty		10,000
Reserves recorded under programs				16,000	14,000
Number of outstanding options				1,752,260	1,823,098
Outstanding options from the computation of diluted earnings per share											496,001
Number of employee stock based compensation plan				3
Stock option compensation expense				272,000	1,325,000
Number of individuals nominated directors	6
Immediate vesting of the options included in stock compensation expense				271,961	1,325,196		700,000
Share based compensation accelerated cost				171,000
Note receivable														$ 564,808